Some Big Pharma heavyweights are duking it out for Brazil's Aché Laboratorios Farmaceuticos. Reuters sources say Pfizer, Novartis and Abbott Laboratories are in the fight, sizing up second-round bids in a deal worth around $5 billion.
Abbott Laboratories is largely focused on medical devices and diagnostics since spinning its innovative drugs business off into AbbVie, but Reuters reports the company is bidding on Brazilian drugmaker Aché Laboratorios Farmaceuticos, which could be worth up to $5 billion.
Novartis lost its last bid for an Indian patent on its cancer drug Glivec. As the nation's Supreme Court prepared to rule Big Pharma braced itself for impact. India has blazed a patent-slashing trail over the last couple of years, issuing a compulsory license for Bayer's cancer drug Nexavar, revoking patents on drugs such as Pfizer's Sutent and Roche's Pegasys, and basically looking the other way when generics makers launch copies of on-patent meds.
Today two countries on opposite sides of the world took radically different stances on pharma patents that will have a big impact on the future of drug R&D.
Sanofi CEO Christopher Viehbacher is barnstorming Asia, spreading news of growth along the way. In Vietnam, he announced a new $75 million plant to boost supplies in the region.
Sanofi already has two manufacturing facilities in Vietnam, but it is not enough to keep up with demand.
U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai.
Florida's bioRASI has completed its acquisition of Sponsors Clinical Research Group, planning to integrate the Ukraine company's capabilities and client roster into its growing Eastern European market share.
India's struggles to regulate its booming clinical research industry are well told, but now China could be headed down the same path, as a Beijing court has taken issue with how trial-runners pay compensation to patients.
Fast-developing countries such as China and India offer the promise of fast growth in drug sales, but it's more difficult to tap those markets--and as Booz & Co. points out in a new report, every country requires its own idiosyncratic strategy.